FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308396325> ?p ?o ?g. }

• W4308396325 abstract "<h3>Background</h3> Botensilimab is a next-generation fragment crystallizable (Fc)-enhanced anti–cytotoxic T-lymphocyte antigen 4 (CTLA-4) antibody that promotes optimized T cell priming, activation, memory formation, and intratumoral regulatory T cell depletion. In patients with advanced solid tumors, botensilimab alone and in combination with balstilimab (anti-programmed cell death protein 1 [PD-1] antibody) demonstrated durable clinical responses in nine different immunotherapy-resistant or poorly immunogenic tumor types. We hypothesize that botensilimab engages multiple immune cell types, including macrophages, dendritic cells (DCs) and natural killer (NK) cells through its enhanced Fc region, to drive deep and broad clinical responses. Here, we applied high-resolution single-cell profiling to demonstrate the differentiated molecular mechanisms of botensilimab relative to a first-generation IgG1 (non-Fc-enhanced) anti-CTLA-4 antibody (bot-IgG1). <h3>Methods</h3> Human <i>ex vivo</i> peripheral blood mononuclear cells were stimulated with staphylococcus enterotoxin antigen followed by treatment with botensilimab, bot-IgG1 or an IgG1 Fc-enhanced isotype control. Secreted cytokines and single-cell measurements of RNA and protein were evaluated over multiple time points and across various immune cell populations. Treatment-specific changes were evaluated within and across donors. <h3>Results</h3> Enhanced interleukin-2 (IL2) secretion in botensilimab-treated cultures relative to bot-IgG1 or isotype control was confirmed across donors. To identify the upstream mechanisms of botensilimab-induced immune activation, RNA and protein expression patterns were interrogated at different time points leading up to maximum IL2 secretion. Sub-clustering of myeloid cells revealed monocyte-, macrophage-, and DC-like populations. Within the myeloid fraction, botensilimab increased the frequency of DCs relative to monocytes and macrophages, and upregulated innate immune signaling pathways distinct from that of first-generation IgG1 anti-CTLA-4. Notably, botensilimab increased the frequency of leukocyte immunoglobulin like receptor B1 (LILRB1 or ILT2)-expressing myeloid cells. Sub-clustering of lymphocytes revealed CD4, CD8, Treg, NK, NKT, and B cell-like populations. Botensilimab increased activation and effector gene expression, including granzyme B and tumor necrosis factor receptor superfamily 9 (TNFRSF9; CD137) in lymphocyte subsets superior to that observed with an IgG1 anti-CTLA-4. <h3>Conclusions</h3> The differentiated ability of botensilimab to reshape myeloid transcriptional programs is consistent with its clinical activity in poorly immunogenic tumors where improved antigen presentation or cross-priming could potentiate responses. Increased expression of LILRB1 and TNFRSF9 in botensilimab-treated immune subsets supports the combination strategies with AGEN1571 (anti-ILT2) and AGEN2373 (anti-CD137) currently under clinical investigation. <h3>Ethics Approval</h3> This study was approved by WCG IRB Ethics Board; approval number 120160614." @default.
• W4308396325 created "2022-11-11" @default.
• W4308396325 creator A5000663868 @default.
• W4308396325 creator A5004819031 @default.
• W4308396325 creator A5032317765 @default.
• W4308396325 creator A5032724293 @default.
• W4308396325 creator A5042363593 @default.
• W4308396325 creator A5047608547 @default.
• W4308396325 creator A5056894275 @default.
• W4308396325 creator A5080150466 @default.
• W4308396325 creator A5081076220 @default.
• W4308396325 date "2022-11-01" @default.
• W4308396325 modified "2023-09-25" @default.
• W4308396325 title "941 Botensilimab modulates innate and adaptive gene expression programs resulting in superior immune stimulation relative to a first-generation anti-CTLA-4 antibody" @default.
• W4308396325 doi "https://doi.org/10.1136/jitc-2022-sitc2022.0941" @default.
• W4308396325 hasPublicationYear "2022" @default.
• W4308396325 type Work @default.
• W4308396325 citedByCount "0" @default.
• W4308396325 crossrefType "proceedings-article" @default.
• W4308396325 hasAuthorship W4308396325A5000663868 @default.
• W4308396325 hasAuthorship W4308396325A5004819031 @default.
• W4308396325 hasAuthorship W4308396325A5032317765 @default.
• W4308396325 hasAuthorship W4308396325A5032724293 @default.
• W4308396325 hasAuthorship W4308396325A5042363593 @default.
• W4308396325 hasAuthorship W4308396325A5047608547 @default.
• W4308396325 hasAuthorship W4308396325A5056894275 @default.
• W4308396325 hasAuthorship W4308396325A5080150466 @default.
• W4308396325 hasAuthorship W4308396325A5081076220 @default.
• W4308396325 hasBestOaLocation W43083963251 @default.
• W4308396325 hasConcept C100701293 @default.
• W4308396325 hasConcept C147483822 @default.
• W4308396325 hasConcept C154317977 @default.
• W4308396325 hasConcept C159654299 @default.
• W4308396325 hasConcept C202751555 @default.
• W4308396325 hasConcept C203014093 @default.
• W4308396325 hasConcept C2776090121 @default.
• W4308396325 hasConcept C2777991845 @default.
• W4308396325 hasConcept C542903549 @default.
• W4308396325 hasConcept C55493867 @default.
• W4308396325 hasConcept C59822182 @default.
• W4308396325 hasConcept C81444415 @default.
• W4308396325 hasConcept C86803240 @default.
• W4308396325 hasConcept C8891405 @default.
• W4308396325 hasConceptScore W4308396325C100701293 @default.
• W4308396325 hasConceptScore W4308396325C147483822 @default.
• W4308396325 hasConceptScore W4308396325C154317977 @default.
• W4308396325 hasConceptScore W4308396325C159654299 @default.
• W4308396325 hasConceptScore W4308396325C202751555 @default.
• W4308396325 hasConceptScore W4308396325C203014093 @default.
• W4308396325 hasConceptScore W4308396325C2776090121 @default.
• W4308396325 hasConceptScore W4308396325C2777991845 @default.
• W4308396325 hasConceptScore W4308396325C542903549 @default.
• W4308396325 hasConceptScore W4308396325C55493867 @default.
• W4308396325 hasConceptScore W4308396325C59822182 @default.
• W4308396325 hasConceptScore W4308396325C81444415 @default.
• W4308396325 hasConceptScore W4308396325C86803240 @default.
• W4308396325 hasConceptScore W4308396325C8891405 @default.
• W4308396325 hasLocation W43083963251 @default.
• W4308396325 hasOpenAccess W4308396325 @default.
• W4308396325 hasPrimaryLocation W43083963251 @default.
• W4308396325 hasRelatedWork W1484759019 @default.
• W4308396325 hasRelatedWork W2022517847 @default.
• W4308396325 hasRelatedWork W2048200509 @default.
• W4308396325 hasRelatedWork W2099244599 @default.
• W4308396325 hasRelatedWork W2102440256 @default.
• W4308396325 hasRelatedWork W2126367104 @default.
• W4308396325 hasRelatedWork W2150135081 @default.
• W4308396325 hasRelatedWork W2220102944 @default.
• W4308396325 hasRelatedWork W339756260 @default.
• W4308396325 hasRelatedWork W4313376859 @default.
• W4308396325 isParatext "false" @default.
• W4308396325 isRetracted "false" @default.
• W4308396325 workType "article" @default.